Form 4: Tandem Diabetes Director Equity Transaction

Director Kathleen McGroddy-Goetz acquired 8,759 shares of Tandem Diabetes Care common stock through the vesting of restricted stock units.

Summary

• Director Kathleen McGroddy-Goetz received 10,220 restricted stock units (RSUs) on May 20, 2026, vesting in one year.
• The director also converted 8,759 vested RSUs into common stock on May 21, 2026.
• Following these transactions, the director holds 26,612 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine administrative filing regarding director equity compensation with no impact on company operations.

Positives

• Director maintains a significant equity stake of 26,612 shares, aligning interests with shareholders.

Negatives

• None identified; this is a routine equity compensation disclosure.

Risks

• None identified; this is a standard regulatory filing regarding director compensation.

Future Outlook

The newly granted 10,220 RSUs are scheduled to vest on May 20, 2027, subject to the terms of the 2023 Long-Term Incentive Plan.

Industry Context

StockSavvy.ai notes that routine equity vesting for directors is standard practice in the medical device sector to ensure long-term retention and alignment with corporate performance goals.

Comparison to Industry Standards

• The equity compensation structure aligns with standard practices for mid-cap medical technology companies.
• Vesting schedules of one year for director RSUs are consistent with industry norms for companies like Insulet or Dexcom.

Corporate Governance

Stakeholder Impact

• No material impact on shareholders, employees, or creditors.

Next Steps

• Vesting of 10,220 RSUs on May 20, 2027.

Key Dates

Keywords

Tandem Diabetes Care, TNDM, Form 4, Director Compensation, Equity Vesting, Insider Transaction